BNGO

Conference call today, May 13, 2026, at 4:30 PM ET SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with first quarter results reflecting the continued engagement of our installed base and positive utilization trends across our optical genome mapping (OGM) and VIA software user community," commented Al Luderer, Ph.D., chairman and interim chief executive officer of Bionano. "The evidence base supporting OGM continues to expand across hematologic malignancies, constitutional genetics, and cell and gene therapy applications, and we are seeing global broad-based adoption at leading institutions. We remain convinced that OGM is on a clear and accelerating path to becoming the standard for comprehensive, genome-wide structural variant analysis. Equally important, we are closing in on a meaningful balance sheet milestone - the expected retirement of our secured convertible debt - which will further strengthen our financial position and allow us to direct future capital towards growing our business.” Q1 2026 Financial Results For the three-month period ended March 31, 2026, as compared to the same period of 2025: Reported total revenue of $6.7 million, representing an increase of 4% from $6.5 million compared to the first quarter of 2025. Consumables revenue was $3.9 million, representing an increase of 20% compared to the first quarter of 2025. Sold 8,178 nanochannel array flow cells in the first quarter of 2026, representing an increase of 17% over the 6,994 flow cells sold in the first quarter of 2025. Generated gross margin of 49%, compared to 46% for the first quarter of 2025, and adjusted gross margin1 of 49%, compared to 46% for the first quarter of 2025. Reduced operating expenses by 2% to $11.1 million and increased adjusted operating expense1 by 7% to $9.1 million. Recent Business Highlights: January 1, 2026, a new Category I CPT code (81354) for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders, went effective on the clinical lab fee schedule (CLFS). The new code covers the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs and is priced above comparable microarray codes. Final 2026 Clinical Lab F...

Bionano Genomics (NASDAQ:BNGO) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. View the webcast at https://edge.media-server.com/mmc/p/6tmtcpga/ Bionano Genomics reported Q1 2026 revenue of $6.7 million, a 4% increase year-over-year, with flow cell sales up 17%. The company emphasized strategic pillars focusing on supporting its installed base, increasing OGM utilization, securing reimbursement, and improving profitability. Significant milestones include a 47% increase in reimbursement rates for OGM and the establishment of a new CPT code for genetic disorders. Gross margin improved to 49% in Q1 2026, and the company aims to reach cash flow breakeven by Q4 2027. Management highlighted strong demand, reduction of debt, and ongoing research publications as key growth drivers. OPERATOR Good day and welcome to the BIONANO first quarter 2026 earnings conference call. Today's conference is being recorded. At this time I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead. Webb Campbell (Moderator) Thank you, Liz and good afternoon everyone. Welcome to the BioNano First Quarter 2026 Financial Results Conference Call. On the call today is Dr. Al Luderer, Chairman and Interim CEO of BioNano, and Mark Adamchak, Bionano's Vice President of Accounting and Principal Accounting Officer. After market close today, Bionano issued a press release announcing its financial Results for the first quarter 2026. A copy of the release can be found on the investor relations page of the Company's website. Certain statements made during this conference call may be forward looking statements. Actual results may differ materially from such statements due to several factors and risks, some of which are identified in Bionano's press release and Bionano's reports filed with the SEC. These forward looking statements are based on information available to Bionano today, May 13, 2026, and the Company assumes no obligation to update statements as circumstances change. During our call, we may refer to certain adjusted financial measures which we believe provide useful information for investors. Reconciliations of these measur...

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management is transitioning the company's core focus from research and development toward commercialization and broad product adoption. The strategic framework has shifted away from aggressive installed base expansion to prioritizing profitable growth with existing routine users. Consumable revenue growth of 20% year-over-year validates the strategy of focusing on high-utilization routine Optical Genome Mapping (OGM) users. Flow cell production constraints experienced in early Q1 are easing, with supply starting to catch up to record unit sales volume. The company is leveraging its VIA software as a 'natural entry point' for labs using NGS and microarrays to eventually adopt the full OGM platform. Profitability improvements are being driven by a disciplined reduction in operating expenses and a revenue mix shift toward higher-margin consumables and software. Full-year 2026 revenue guidance of $30 million to $33 million assumes continued growth in recurring revenue and easing supply chain constraints. Management expects flow cell production to continue improving throughout the remainder of 2026 to meet strong demand. The company aims to reduce cash burn significantly by Q4 2027, though it has not provided a specific date for reaching cash flow breakeven. The retirement of all outstanding senior secured convertible debt in May 2026 is expected to simplify the financial profile and increase strategic flexibility. Future growth is expected to be driven by the implementation of new CPT reimbursement codes and upcoming clinical publications that expand OGM's evidence base. A 47% increase in the payment determination for the Category 1 CPT code for OGM in hematologic malignancies took effect January 1, 2026. A new Category 1 CPT code for constitutional genetic disorders was established with a final payment determination of $1,263.53. Dr. Al Luderer stepped in as Interim CEO following the departure of long-time CEO Erik Holmlin, who remains in an advisory role. Software revenue declined 40% year-over-year due to a large non-recurring sale in the prior year that satisfied a customer's multi-year needs. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management ex...

This article first appeared on GuruFocus. Release Date: May 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Bionano Genomics Inc (NASDAQ:BNGO) reported a 17% year-over-year increase in flow cell sales, reaching a record volume for any Q1. Consumable revenue increased by 20% year-over-year, indicating strong growth and alignment with the company's strategy. The company achieved a 49% gross margin in Q1 2026, up from 46% in Q1 2025, reflecting improved operational efficiencies. Significant reimbursement milestones were achieved with a 47% increase in payment determination for OGM in hematologic malignancies and a new CPT code for constitutional genetic disorders. Publications describing the utility of OGM for rare diseases increased by 56% year-over-year, with a 158% increase in genomes published, showcasing growing academic and clinical interest. Software revenue decreased by 40% year-over-year due to a large prior year sale that fulfilled customer needs for 2025 and 2026. The company does not expect to reach cash flow break-even by the end of 2026, indicating ongoing financial challenges. Despite revenue growth, the company faced supply constraints in flow cell production, although improvements are expected. Operating expenses increased to $9.1 million in Q1 2026 from $8.5 million in Q1 2025, indicating higher costs. The company is undergoing a leadership transition, which may pose risks to business continuity and strategic execution. Warning! GuruFocus has detected 3 Warning Signs with BNGO. Is BNGO fairly valued? Test your thesis with our free DCF calculator. Q: Could you provide some comments regarding if you expect the company to achieve operating cash flow break-even either late this year or sometime in 2027? A: No, we do not expect to reach cash flow break-even by the end of 2026. We are taking necessary steps to reduce the burn as much as possible by Q4 of 2027, but we're not providing guidance as to whether or not we can achieve that. - Mark Adamchak, Vice President of Accounting and Principal Accounting Officer. Q: Do you expect any additional catalysts that could potentially occur either later this year or in 2027 that could help to improve gross margin or further reduce operating expenses? A: Several catalysts are expected this year. The first is the CPT code and strong reimbursement, w...

This article first appeared on GuruFocus. Bionano Genomics Inc (NASDAQ:BNGO) is set to release its Q1 2026 earnings on May 13, 2026. The consensus estimate for Q1 2026 revenue is $6.57 million, and the earnings are expected to come in at -$0.95 per share. The full year 2026's revenue is expected to be $32.14 million, and the earnings are expected to be -$2.71 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 3 Warning Signs with BNGO. Is BNGO fairly valued? Test your thesis with our free DCF calculator. Over the past 90 days, revenue estimates for Bionano Genomics Inc (NASDAQ:BNGO) have declined from $35.08 million to $32.14 million for the full year 2026, and from $51.92 million to $43.30 million for 2027. Earnings estimates have improved, increasing from -$3.22 per share to -$2.71 per share for the full year 2026, and from -$1.22 per share to -$1.11 per share for 2027. In the previous quarter ending December 31, 2025, Bionano Genomics Inc's (NASDAQ:BNGO) actual revenue was $7.95 million, which beat analysts' revenue expectations of $7.85 million by 1.25%. Bionano Genomics Inc's (NASDAQ:BNGO) actual earnings were -$0.03 per share, which exceeded analysts' earnings expectations of -$1.40 per share by 97.86%. After releasing the results, Bionano Genomics Inc (NASDAQ:BNGO) was down by 19.18% in one day. Based on the one-year price targets offered by 2 analysts, the average target price for Bionano Genomics Inc (NASDAQ:BNGO) is $5.00, with a high estimate of $6.00 and a low estimate of $4.00. The average target implies an upside of 293.70% from the current price of $1.27. Based on GuruFocus estimates, the estimated GF Value for Bionano Genomics Inc (NASDAQ:BNGO) in one year is $1.94, suggesting an upside of 52.76% from the current price of $1.27. Based on the consensus recommendation from 3 brokerage firms, Bionano Genomics Inc's (NASDAQ:BNGO) average brokerage recommendation is currently 2.3, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +100.00%. A quarter ago, it was expected that this drugmaker would post a loss of $0.07 per share when it actually produced a loss of $0.04, delivering a surprise of +42.86%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Lexicon, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $21.1 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 141.91%. This compares to year-ago revenues of $1.26 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Lexicon shares have added about 39.1% since the beginning of the year versus the S&P 500's gain of 7.6%. While Lexicon has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Lexicon was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy)...

SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2026 and to highlight recent corporate progress. Conference Call & Webcast Details Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionano.com/ for at least 30 days. Contacts Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 [email protected] Investor Relations: Webb Campbell Gilmartin Group +1 (415) 520-5817 [email protected]

Transitioned from aggressive installed base expansion to a focus on profitable growth from high-volume, routine-use customers and selective acquisition. Identified a 'routine-use' cohort comprising 40% of customers who drive 83% of consumables revenue, averaging double the revenue of the general base. Attributed Q4 revenue declines to supply constraints from a manufacturing partner for silicon wafers, creating a backlog of consumable demand entering 2026. Achieved a 1,200 basis point year-over-year improvement in full-year non-GAAP gross margin despite lower total revenue, reflecting enhanced business efficiencies. Executed a massive cost reduction program, removing approximately $100 million in annualized non-GAAP operating expenses and reducing headcount by over 300 since Q2 2023. Narrowed geographic focus to North America, Western Europe, and Israel to concentrate resources on the most productive market regions. Reported that existing customer consumable sales grew 5% for the full year when excluding flow cells tied to new system sales, indicating underlying base stability. Initiated 2026 revenue guidance of $30 million to $33 million, assuming growth will be driven by converting routine-use customers to validated protocols. Expects a significant catalyst from the 47% increase in the Medicare payment determination for the hematologic malignancy CPT code, now priced at $1,853.22. Anticipates consumable supply constraints will ease over the next couple of quarters, allowing the company to realize the healthy backlog of demand. Projects cash runway to extend into 2027, supported by the expected full retirement of senior secured convertible debt in May 2026. Forecasts margin expansion to continue in line with revenue growth as product mix shifts further toward high-margin consumables and software. Achieved record OGM publication volume in 2025, with peer-reviewed publications increasing 25% year-over-year to 136 new entries. Established a second Category I CPT code for constitutional genetic disorders with a final price determination of $1,263.53 for the 2026 schedule. Noted a 22% decline in Q4 software revenue due to the timing of specific orders that were pulled forward into prior quarters. Highlighted the emergence of regional OGM consortia, such as FROG in France, as a shift toward community-led advocacy rather than company-driven promotion. Our analysts...

Conference call today, March 23, 2026, at 4:30 PM ET SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano. “Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base. The global OGM community continues to show extraordinary energy, from the record attendance and engagement at the Bionano Symposium 2026 – where leading laboratories described scaling OGM workflows to potentially thousands of samples per year – to the continued expansion of the published body of clinical research evidence supporting OGM across hematologic malignancies, constitutional genetics, and cell and gene therapy applications. We also saw the 47% increase in the 2026 Clinical Lab Fee Schedule payment determination for the Category I CPT code for OGM use in hematologic malignancies take effect. Together, these developments reinforce our confidence that OGM is becoming the standard for comprehensive, genome-wide structural variant analysis, and that Bionano is well-positioned to drive continued utilization growth and sustainable progress in 2026." Q4 2025 Financial Results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $8.0 million, representing a decrease of 3% from $8.2 million in the fourth quarter of 2024. Consumables and software revenues decreased 1%. The prior year period included $2.8 million in instrument revenue, compared to $2.7 million in the fourth quarter of 2025. Sold 7,554 nanochannel array flowcells in the fourth quarter of 2025, representing a decrease of 6% over the 8,058 flowcells sold in the fourth quarter of 2024. Installed 9 new OGM systems and brought 6 back to reach an installed base of 387 at quarter-end, representing a 4% increase over the 371 installed systems reported at the end of the fourth quarter of 2024. Generated gross margin of 43%, compared to 42% for the fourth quarter of 2024, and non-GAAP gross margin1 of 43%, compared to 42% for the fourth quarter of 2024. Reduced operating expenses by 22% to...

This article first appeared on GuruFocus. Q4 2025 Revenue: $8 million, down 3% from $8.2 million in Q4 2024. Full Year 2025 Revenue: $28.5 million, down 7% from $30.8 million in 2024. Non-GAAP Gross Margin Q4 2025: 43%, up from 42% in Q4 2024. Non-GAAP Gross Margin Full Year 2025: 47%, up from 35% in 2024. Non-GAAP Operating Expense Q4 2025: $9.7 million, down 9% year-over-year. Non-GAAP Operating Expense Full Year 2025: $36.6 million, down 47% from $68.9 million in 2024. Cash and Equivalents End of 2025: $29.6 million, including $10.3 million subject to restrictions. Flow Cells Sold Q4 2025: 7,554, down 6% year-over-year. Flow Cells Sold Full Year 2025: 30,171, down 0.4% year-over-year. OGM Systems Installed Q4 2025: 9 systems. OGM Systems Installed Full Year 2025: 32 systems, exceeding guidance of 15 to 20. Consumables and Software Revenue Q4 2025: Decreased by 1% to $4.8 million. Consumables and Software Revenue Full Year 2025: Grew 7% from $19 million to $20.4 million. Revenue Guidance for Full Year 2026: $30 million to $33 million, representing 5% to 16% growth over 2025. Revenue Guidance for Q1 2026: $6.5 million to $6.7 million, representing flat to 3% growth over Q1 2025. Warning! GuruFocus has detected 4 Warning Signs with BNGO. Is BNGO fairly valued? Test your thesis with our free DCF calculator. Release Date: March 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Bionano Genomics Inc (NASDAQ:BNGO) achieved a non-GAAP gross margin of 47% for the full year 2025, up from 35% in 2024, indicating improved operational efficiency. The company successfully reduced its non-GAAP operating expenses by 47% year-over-year, showcasing effective cost management. Bionano Genomics Inc (NASDAQ:BNGO) exceeded its original guidance by installing 32 OGM systems in 2025, surpassing the expected range of 15 to 20 installations. The company reported a significant increase in publications related to its technology, with 450 publications in 2025, up from 359 in 2024, reflecting growing acceptance and interest in its products. Bionano Genomics Inc (NASDAQ:BNGO) has a strong cash position, with $29.6 million in cash, cash equivalents, and available-for-sale securities, extending its cash run rate into 2027. Revenue for the fourth quarter of 2025 was $8 million, down 3% from the previous year, indicating a decline i...

Image source: The Motley Fool. Monday, March 23, 2026 at 4:30 p.m. ET Chief Executive Officer — Erik Holmlin Principal Accounting Officer — Mark Adamczak Need a quote from a Motley Fool analyst? Email [email protected] Erik Holmlin: Thank you, Webb. And good afternoon, everyone. I am excited to share our fourth quarter and full year 2025 results with you today, as well as to provide you with our expectations for 2026. I want to begin, however, with the context of the broader space we are aiming to impact, namely pathology, which is the discipline that investigates the causes, developments, and effects of disease. Our products and solutions are focused on transforming pathology from tedious, slow, costly, and labor-intense analog workflows of the past towards streamlined workflows of a digital future defined by technology and platform consolidation, automation, and powerful AI-driven software. Our work in 2025, including the hundreds of publications and presentations by our users, demonstrated meaningful progress toward this goal and the significant value represented by this opportunity. As part of today's call, I want to take time to review the strategy we began implementing in September 2024, our progress in 2025, and summarize key takeaways from a deep dive into our customer base, revealing the composition of our most profitable customer profile. First, however, I want to ask Mark Adamczak, our principal accounting officer, to review our Q4 and 2025 financial highlights. Mark? Mark Adamczak: Thanks, Erik. Revenue for Q4 2025 was $8.0 million, which is down 3% from $8.2 million in Q4 2024 but at the high end of our preannounced range of $7.8 million to $8.0 million. We sold 7,554 nanochannel array flow cells in Q4, which was down 6% year over year, but it is worth noting that late in Q4, our manufacturing partner that makes the silicon wafers for our chip consumables experienced delays. As a result, supply was constrained against higher consumable demand. We entered 2026 with a healthy backlog of consumables demand that we expect to realize in the coming quarters as these constraints ease. For the full year 2025, revenue was $28.5 million, down 7% from $30.8 million in 2024. After adjusting for $1.7 million in clinical services in 2024, core revenue was down 2%. We sold 30,171 flow cells in 2025, down just 0.4% year over year. We also installed nine OGM systems i...